Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer:: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer:: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial
复制标题
DOI：
10.1200/jco.2007.11.4991
复制
发表时间：
2007-08-01
影响因子：
45.3
通讯作者：
Collette, Laurence
中科院分区：
文献类型：
--
作者：
Bartelink, Harry;Horiot, Jean-Claude;Collette, Laurence
目的探讨 16 Gy 加强放射剂量对接受保乳治疗的 I 期和 II 期乳腺癌患者的局部控制、纤维化和总生存期的长期影响。 患者和方法 总共 5,318 例显微镜下完全切除并接受 50 Gy 全乳照射的患者被随机分配接受 16 Gy 加强剂量（2,661 名患者）或不接受加强剂量（2,661 名患者）。 2,657 名患者），中位随访时间为 10.8 年。结果中位年龄为 55 岁。据报道，278 名未接受加强治疗的患者与 165 名接受加强治疗的患者首次治疗失败，导致局部复发； 10 年时，无加强组和加强组的局部复发累积发生率分别为 10.2% 和 6.2% ( P < .0001)。局部复发的风险比为 0.59（0.46 至 0.76），支持加强治疗，每个年龄组没有统计学上显着的相互作用。每个年龄组 10 岁时绝对风险降低幅度在患者中最大
PurposeTo investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fibrosis, and overall survival for patients with stage I and II breast cancer who underwent breast-conserving therapy.Patients and MethodsA total of 5,318 patients with microscopically complete excision followed by whole-breast irradiation of 50 Gy were randomly assigned to receive either a boost dose of 16 Gy ( 2,661 patients) or no boost dose ( 2,657 patients), with a median follow-up of 10.8 years.ResultsThe median age was 55 years. Local recurrence was reported as the first treatment failure in 278 patients with no boost versus 165 patients with boost; at 10 years, the cumulative incidence of local recurrence was 10.2% versus 6.2% for the no boost and the boost group, respectively ( P < .0001). The hazard ratio of local recurrence was 0.59 ( 0.46 to 0.76) in favor of the boost, with no statistically significant interaction per age group. The absolute risk reduction at 10 years per age group was the largest in patients